EPA and DHA differentially affect in vitro inflammatory cytokine release by peripheral blood mononuclear cells from Alzheimer's patients

Current Alzheimer Research

Volumn 9, Issue 8, 2012, Pages 913-923

  Serini, Simona ^a   Bizzarro, Alessandra ^a   Piccioni, Elisabetta ^a   Fasano, Elena ^a   Rossi, Concetta ^a   Lauria, Alessandra ^a   Cittadini, Achille R M ^a   Masullo, Carlo ^a   Calviello, Gabriella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer's disease; Cytokines; DHA; EPA; Inflammation

Indexed keywords

CYTOKINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; CELLS, CULTURED; CYTOKINES; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MALE;

EID: 84858951813     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803251147     Document Type: Article

References (56)

1. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 13: 63-8 (1999).
2. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23: 9796-804 (2003).
3. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, et al. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 5: 51 (2008).
4. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 19: 355-61 (2010).
5. Fiala M. Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside. CNS Neurol Disord Drug Targets 9: 192-6 (2010).
6. McGeer PL, Sibley J. Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 26: 1199-203 (2005)
7. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 19: 392-8 (2009).
8. Forlenza OV, Diniz BS, Talib LL, Mendonça VA, Ojopi EB, Gattaz WF, et al. Increased serum IL-1beta level in Alzheimer's dis ease and mild cognitive impairment. Dement Geriatr Cogn Disord 28: 507-12 (2009).
9. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421 (2000).
10. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, Rao ML, et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol 45: 666-8 (1999).
11. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365-8 (2000).
12. Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C, et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 25: 1009-15 (2004).
13. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acutephase state in Alzheimer's disease cortices. FEBS Lett 285: 111-4 (1991).
14. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611-5 (1989).
15. Hüll M, Lieb K, Fiebich BL. Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr Med Chem 9: 83-8 (2002).
16. Lombardi VR, García M, Rey L, Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol 97: 163-71 (1999).
17. Remarque EJ, Bollen EL, Weverling-Rijnsburger AW, Laterveer JC, Blauw GJ, Westendorp RG. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp Gerontol 36: 171-6 (2001).
18. Calviello G, Serini S, Piccioni E. Alzheimer's disease and n-3 polyunsaturated fatty acids: Beneficial effects and possible molecular pathways involved. Curr Signal Transduct Ther 3: 152-7 (2008).
19. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42: 776-82 (1997).
20. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 325: 932-3 (2002).
21. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60: 940-6 (2003).
22. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85: 1142-7 (2007).
23. Heude B, Ducimetiere P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study. Am J Clin Nutr 77: 803-8 (2003).
24. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89: 483-9 (2003).
25. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26: 421-5 (1991).
26. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35: 1305-12 (2000).
27. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63: 1545-50 (2006).
28. Nauroth JM, Liu YC, Van Elswyk M, Bell R, Hall EB, Chung G, et al. Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids 45: 375-84 (2010).
29. Pestka JJ. n-3 polyunsaturated fatty acids and autoimmunemediated glomerulonephritis. Prostaglandins Leukot Essent Fatty Acids 82: 251-8 (2010).
30. Lund T, Mangsbo SM, Scholz H, Gjorstrup P, Tötterman TH, Korsgren O, et al. Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Exp Clin Endocrinol Diabetes 118: 237-44 (2010).
31. Olveira G, Olveira C, Acosta E, Espíldora F, Garrido-Sánchez L, García-Escobar E, et al. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol 46: 70-7 (2010).
32. Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, Cherubini A. Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des 15: 4135-48 (2009).
33. Oh da Y, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-98 (2010).
34. Sijben JW, Calder PC. Differential immunomodulation with longchain n-3 PUFA in health and chronic disease. Proc Nutr Soc 66: 237-59 (2007).
35. Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A, Faxén Irving G, et al. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 87: 1616-22 (2008).
36. Mullen A, Loscher CE, Roche HM. Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages. J Nutr Biochem 21: 444-50 (2010).
37. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 61: 345-58. (2002).
38. Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77: 327-35 (2007).
39. Moison RM, Beijersbergen Van Henegouwen GM. Dietary eicosapentaenoic acid prevents systemic immunosuppression in mice induced by UVB radiation. Radiat Res 156:36-44 (2001).
40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984):
41. Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, Kott E, et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 52: 147-52 (1994).
42. Ranjan D, Johnston TD, Wu G, Elliott L, Bondada S, and Nagabhushan M. Curcumin Blocks Cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation. J Surg Res 77: 174-8 (1998).
43. Tyrsted G, Munch-Petersen B. Early effects of phytohemagglutinin on induction of DNA polymerase, thymidine kinase, deoxyribonucleoside triphosphate pools and DNA synthesis in human lymphocytes. Nucleic Acids Res 4: 2713-23 (1977).
44. Hsi ED, Remick DG. Monocytes are the major producers of interleukin-1 beta in an ex vivo model of local cytokine production. J Interferon Cytokine Res 15(1): 89-94 (1995).
45. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM: Production of hybridomas growth factor by human monocytes. Eur J Immunol 17: 1411 (1987).
46. Pawlosky RJ, Hibbeln JR, Salem N Jr. Compartmental analyses of plasma n-3 essential fatty acids among male and female smokers and nonsmokers. J Lipid Res 48: 935-43 (2007).
47. Magaki S, Mueller C, Dickson C, Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42: 233-40 (2007).
48. Chen G, Nayan M, Duong M, Asenjo JF, Ge Y, Chiu RC, et al. Marrow stromal cells for cell-based therapy: the role of antiinflammatory cytokines in cellular cardiomyoplasty. Ann Thorac Surg 90: 190-7 (2010).
49. Alessandri JM, Guesnet P, Vancassel S, Astorg P, Denis I, Langelier B, et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 44: 509-38 (2004).
50. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr 137: 855-9 (2007).
51. Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr 143: S1-8 (2003).
52. Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev 64: S24-33 (2006).
53. Fleith M, Clandinin MT. Dietary PUFA for preterm and term infants: review of clinical studies. Crit Rev Food Sci Nutr 45: 205-29 (2005).
54. Favrelière S, Perault MC, Huguet F, De Javel D, Bertrand N, Piriou A, et al. DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol Aging 24: 233-43 (2003).
55. Gamoh S, Hashimoto M, Hossain S, Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28: 266-70 (2001).
56. Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol 181: 3877-86 (2008).